Comparative Pharmacology
Head-to-head clinical analysis: ADLARITY versus COGNEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLARITY versus COGNEX.
ADLARITY vs COGNEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADLARITY is a transdermal formulation of donepezil, a reversible acetylcholinesterase inhibitor that increases acetylcholine levels in the central nervous system, improving cholinergic neurotransmission in the cerebral cortex.
Reversible acetylcholinesterase inhibitor, increases acetylcholine concentration at cholinergic synapses.
10 mg transdermal patch applied once daily to clean, dry, hairless skin on the back, chest, or upper arm.
Initial dose 10 mg orally 4 times daily (40 mg/day); may increase by 10 mg/day every 6 weeks up to 160 mg/day (40 mg 4 times daily).
None Documented
None Documented
Terminal half-life approximately 70 hours (range 50-100 hours); steady-state achieved within 14-21 days; once-daily dosing due to long half-life.
Terminal elimination half-life is approximately 7-10 hours; clinical context: allows twice-daily dosing in most patients.
Renal: ~60% as unchanged donepezil and metabolites (primarily donepezil, 6-O-desmethyl donepezil, and donepezil-N-oxide); fecal: ~15-20% (biliary excretion of metabolites); minor via urine as conjugates.
Primarily renal (approximately 40-60% as unchanged drug and metabolites) and biliary/fecal (approximately 20-30%).
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor